• Nippon Shinyaku signed an exclusive license with Aquelys Therapeutics granting worldwide rights to develop, manufacture, commercialize NS-025.
• Nippon Shinyaku retained rights to develop, commercialize NS-025 for certain indications in Japan.
• Aquelys will advance NS-025 into studies targeting Sjögren’s-related xerostomia; the compound is in Phase 1 under Nippon Shinyaku.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein.